Runhong Wei

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Peritoneal Dialysis

Multiple Myeloma

Prognostic Factors

Top Venues

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)
Qing Ming Wang, Runhong Wei, Shu-Fang Guo, Chao Min, Xiong Zhong, Hui Huang, Zhi Cheng
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer gene therapy 31 (3) (2023)